Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
21 maj, 07:05
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
Oslo, Norway, May 21, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) today releases its results for the first quarter of 2026.
Lytix continued to execute on its established development strategy during the first quarter and post-quarter-end period, with progress across its lead asset ruxotemitide and broader oncolytic molecule platform. Clinical development priorities for 2026 and 2027 remain on track, with registrational path planning advancing for ruxotemitide in neoadjuvant melanoma.
Ruxotemitide is supported by a strong and consistent clinical foundation across melanoma and basal cell carcinoma, including evidence of local tumor killing, systemic immune activation, durable responses, and a manageable safety profile. The Company is focused on advancing ruxotemitide toward its next stage of development through disciplined clinical planning, regulatory engagement, and continued execution.
Q1 2026 highlights and developments
- The NeoLIPA Phase II neoadjuvant melanoma study continued to progress:
- 20 of 27 patients enrolled as of May 2026
- A new clinical site opened at Haukeland to support continued enrollment momentum and reduce execution risk
- Top-line results remain expected in the second half of 2026
- New ATLAS-IT-05 data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026 in San Diego. Ruxotemitide continued to demonstrate clinical and strategic relevance in advanced melanoma:
- Tumor shrinkage was observed in distant, non-treated lesions in patients who had failed prior immunotherapy
- Durable responses and disease control were observed in difficult-to-treat melanoma
- Overall survival data further supported the clinical profile of ruxotemitide in combination with pembrolizumab
- Additional ATLAS-IT-05 data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2026 in Chicago
- Verrica Pharmaceuticals presented new data for ruxotemitide (VP-315), on May 15, 2026 at the Investigative Dermatology Annual Meeting in Chicago
- Cash and short-term financial investments amounted to NOK 120 million as of March 31, 2026
- Total operating expenses amounted to NOK 26.8 million for the first quarter of 2026
Ruxotemitide remains Lytix’s lead development priority. The Company is advancing the asset in neoadjuvant melanoma through the NeoLIPA study and structured planning for a potential registrational study. In parallel, Verrica Pharmaceuticals continue preparations for a registrational Phase 3 trial with ruxotemitide as a non-surgical treatment for basal cell carcinoma.
Lytix is continuing to advance LTX-401, its proprietary preclinical oncolytic small molecule designed for deep-seated tumors. The Company is evaluating the optimal clinical development strategy for LTX-401 and continues to pursue partnering discussions to support future value creation.
Webcast details
The results will be presented in a webcast with CEO Øystein Rekdal, CFO Gjest Breistein and CMO Karim Benhadji today.
Date: Thursday, May 21, 2026
Time: 14:00 CET
Questions may be submitted in advance to: post@lytixbiopharma.com
The presentation and Q&A session will be conducted in English. You can view the live event by registering here: https://qcnl.tv/p/s6roJjTDW6gVSNwfqof5Rw
A recording will be available after the event at:
https://www.lytixbiopharma.com/investors/reports-and-presentations/financial-reports
For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com
About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide, formerly LTX-315, is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com
Ämnen i artikeln
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
21 maj, 07:05
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
Oslo, Norway, May 21, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) today releases its results for the first quarter of 2026.
Lytix continued to execute on its established development strategy during the first quarter and post-quarter-end period, with progress across its lead asset ruxotemitide and broader oncolytic molecule platform. Clinical development priorities for 2026 and 2027 remain on track, with registrational path planning advancing for ruxotemitide in neoadjuvant melanoma.
Ruxotemitide is supported by a strong and consistent clinical foundation across melanoma and basal cell carcinoma, including evidence of local tumor killing, systemic immune activation, durable responses, and a manageable safety profile. The Company is focused on advancing ruxotemitide toward its next stage of development through disciplined clinical planning, regulatory engagement, and continued execution.
Q1 2026 highlights and developments
- The NeoLIPA Phase II neoadjuvant melanoma study continued to progress:
- 20 of 27 patients enrolled as of May 2026
- A new clinical site opened at Haukeland to support continued enrollment momentum and reduce execution risk
- Top-line results remain expected in the second half of 2026
- New ATLAS-IT-05 data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026 in San Diego. Ruxotemitide continued to demonstrate clinical and strategic relevance in advanced melanoma:
- Tumor shrinkage was observed in distant, non-treated lesions in patients who had failed prior immunotherapy
- Durable responses and disease control were observed in difficult-to-treat melanoma
- Overall survival data further supported the clinical profile of ruxotemitide in combination with pembrolizumab
- Additional ATLAS-IT-05 data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2026 in Chicago
- Verrica Pharmaceuticals presented new data for ruxotemitide (VP-315), on May 15, 2026 at the Investigative Dermatology Annual Meeting in Chicago
- Cash and short-term financial investments amounted to NOK 120 million as of March 31, 2026
- Total operating expenses amounted to NOK 26.8 million for the first quarter of 2026
Ruxotemitide remains Lytix’s lead development priority. The Company is advancing the asset in neoadjuvant melanoma through the NeoLIPA study and structured planning for a potential registrational study. In parallel, Verrica Pharmaceuticals continue preparations for a registrational Phase 3 trial with ruxotemitide as a non-surgical treatment for basal cell carcinoma.
Lytix is continuing to advance LTX-401, its proprietary preclinical oncolytic small molecule designed for deep-seated tumors. The Company is evaluating the optimal clinical development strategy for LTX-401 and continues to pursue partnering discussions to support future value creation.
Webcast details
The results will be presented in a webcast with CEO Øystein Rekdal, CFO Gjest Breistein and CMO Karim Benhadji today.
Date: Thursday, May 21, 2026
Time: 14:00 CET
Questions may be submitted in advance to: post@lytixbiopharma.com
The presentation and Q&A session will be conducted in English. You can view the live event by registering here: https://qcnl.tv/p/s6roJjTDW6gVSNwfqof5Rw
A recording will be available after the event at:
https://www.lytixbiopharma.com/investors/reports-and-presentations/financial-reports
For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com
About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide, formerly LTX-315, is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com
Ämnen i artikeln
SpaceX mot börsen
SpaceX mot börsen
Marknadsöversikt
1 DAG %
Senast
1 mån
